Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled study of SAR444656 in moderate to severe hidradenitis suppurativa
2023-504328-25-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SAR444656 with Placebo (2 arms). Primary endpoint: Percent change from baseline in total abscess and inflammatory nodule count. Planned start Dec 2023; status: authorised.
02
Drugs
SAR444656
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-504328-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504328-25-00.